Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.41 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094697 | 0.83 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL1898922 | 0.71 | — | — | |
| SCHEMBL2061817 | 0.70 | ITGB2 (0.52) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL7471891 | 0.68 | CHRNB4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL102031 | 0.65 | NISCH (0.34) | LMNAHTTCHRNB4CHRNA3CHRNB2 | |
| SCHEMBL21294575 | 0.64 | ADRA2A (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23646856 | 0.63 | SMN1; SMN2 (0.65) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL11406989 | 0.62 | ITGB2 (1.00) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL6791411 | 0.62 | ITGB2 (1.00) | ITGB2ICAM1ITGALLMNACRHBP | |
| SCHEMBL11399163 | 0.62 | ITGB2 (1.00) | ITGB2ICAM1ITGALLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | ITGB2 4318/4885ICAM1 2617/4885ITGAL 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.